IM8N.F Insmed Incorporated

Healthcare Biotechnology Frankfurt Exchange
106.52 EUR
Close of Nov 13, 2026
78.77 185.00
Market cap
EUR 23.4B
P/E
-
P/B
36.17x
ROE
-50.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IM8N.F undervalued?

Graham number

The Graham number of Insmed Incorporated cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Insmed Incorporated fundamental analysis

No fundamental analysis for Insmed Incorporated yet.

Insmed Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Insmed Incorporated

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral r…

Full company profile